Longevity startup NewLimit secures $435 million Series C as it prepares first liver drug trial
NewLimit, a longevity‑focused biotech founded in 2021, announced a Series C financing that brought in $435 million, pushing its valuation to about $3.1 billion.
The round was led by Founders Fund and included participation from Thrive Capital, Lilly Ventures, and individual investors such as Nat Friedman and Daniel Gross.
With the new capital, NewLimit plans to start its first clinical trial of a liver‑targeted medicine, marking the company’s transition from early‑stage development to human testing.
The rapid fundraising activity follows a $130 million Series B raised last year, underscoring strong investor interest in longevity therapeutics.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Longevity startup NewLimit raises $435 million ahead of first clinical trial”
read at STAT ↗
comments(0)
5-min edit window · permanent after that